(127 days)
Not Found
No
The device description details a homogeneous enzyme immunoassay based on recombinant DNA technology and spectrophotometric measurement, with no mention of AI or ML algorithms for data analysis or interpretation.
No.
This device is an in vitro diagnostic (IVD) assay used for the qualitative determination of amphetamines in human urine, aiding in the diagnosis of amphetamine use or overdose. It does not directly provide therapy or treatment.
Yes.
The "Intended Use / Indications for Use" section states, "Measurements are used as an aid in the diagnosis and treatment of amphetamine use or overdose." This indicates its role in the diagnostic process.
No
The device description clearly states it consists of "AmphAssure Reagents, AmphAssure Calibrator, Standard, and Control Set," which are physical components, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the assay is for the "in vitro qualitative determination of amphetamines in human urine". "In vitro" means "in glass" or "outside the body," which is a key characteristic of IVDs.
- Sample Type: The device analyzes "human urine," which is a biological specimen taken from the body.
- Purpose: The purpose is to aid in the "diagnosis and treatment of amphetamine use or overdose," which is a diagnostic purpose.
- Device Description: The description details a laboratory test using reagents and an automated clinical chemistry analyzer, which is typical for IVD devices.
N/A
Intended Use / Indications for Use
The CEDIA® DAU AmphAssure Assay is a homogeneous enzyme immunoassay for the in vitro qualitative determination of amphetamines in human urine on automated clinical chemistry analyzers. This device is used as an accessory to immunoassay screening tests to reduce the number of false positive results needing confirmation testing. Measurements are used as an aid in the diagnosis and treatment of amphetamine use or overdose.
The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. GCMS is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug of abuse test result particularly when preliminary positive test results are used.
Product codes
DKZ, DKB
Device Description
The CEDIA® DAU AmphAssure assay uses recombinant DNA technology (US Patent No. 4708929) to produce a unique homogeneous enzyme immunoassay system. This assay is based on the bacterial enzyme B-galactosidase, which has been genetically engineered into two inactive fragments. These fragments spontaneously reassociate to form fully active enzyme that, in the assay format, cleaves a substrate, generating a color change that can be measured spectrophotometrically. The CEDIA DAU AmphAssure assay is a unique test for identification of amphetamines in urine and for the elimination of false positive results due to other cross-reactant substances. Most cross-reactive substances must be present in high concentrations compared to amphetamines in order to give a false-positive result in immunoassay based methods that detect amphetamines. AmphAssure employs the addition of a limited amount of a neutralizing antibody to amphetamine and methamphetamine to neutralize the signal in a true positive sample, without any effect on the signal from a sample containing a high concentration of cross-reactive substance. The neutralizing antibody does not bind the labeled conjugate in the assay, so that its primary effect is to reduce the signal resulting from amphetamines in the sample. Samples containing amphetamines can be distinguished from false-positive samples by the difference in signal before and after addition of the neutralizing antibody. Two analyzer channels are programmed with identical test parameters for the CEDIA AmphAssure assay; reagents without neutralization antibodies are assigned to the first channel, and the reagents with neutralization antibodies are assigned to the second channel. A calculated test (channel three) is programmed to give the difference in results between the first and second channel. Calibrators, controls and patient samples are tested on both channels.
The device consists of following:
AmphAssure Reagents:
1 EA Reconstitution Buffer Piperazine-N, N-bis [2-ethanesulfonic acid] buffer, buffer salts, stabilizer, and preservative la
EA Reagent 0.16 g/l Enzyme Acceptor (microbial), 7 mg/l mouse monoclonal antibodies reactive to d-amphetamine and 7 mg/l mouse monoclonal antibodies reactive to d-methamphetamine, buffer salts, detergent, and preservative
2 ED Reconstitution Buffer Piperazine-N, N-bis [2-ethanesulfonic acid] buffer; buffer salts, and preservative
2a ED Reagent 7.1 µg/l Enzyme Donor (microbial) conjugated to d-amphetamine and 11.3 µg/l Enzyme Donor (microbial) conjugated to d-methamphetamine, 1.7g/l chlorophenol red-b-D-galactopyranoside, stabilizer, and preservative
3 EA Reconstitution Buffer 350 mg/l mouse monoclonal antibodies reactive to d-amphetamine and d-methamphetamine, Piperazine-N, N-bis [2-ethanesulfonic acid] buffer, buffer salts, stabilizer, and preservative
3a EA Reagent 0.16 g/l Enzyme Acceptor (microbial), 7 mg/l mouse monoclonal antibodies reactive to d-amphetamine and 7 mg/l mouse monoclonal antibodies reactive to d-methamphetamine, buffer salts, detergent, and preservative
4 ED Reconstitution Buffer Piperazine-N, N-bis [2-ethanesulfonic acid] buffer; buffer salts, and preservative
4a ED Reagent 7.1 µg/l Enzyme Donor (microbial) conjugated to d-amphetamine and 11.3 µg/l Enzyme Donor (microbial) conjugated to d-methamphetamine, 1.7 g/l chlorophenol red-b-D-galactopyranoside, stabilizer, and preservative
AmphAssure Calibrator, Standard, and Control Set:
• Upper Limit Standard 15,000 ng/ml d-methamphetamine in normal urine with preservative
• Cut-off Calibrator 375 ng/ml d-methamphetamine and 225K ng/ml pseudoephedrine in normal urine with preservative
False Positive Control 500K ng/ml pseudoephedrine in normal urine with preservative
AmphAssure Calibrator, Standard and Control Kit is designed for use with the AmphAssure assay only and will be packaged separately.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
human urine
Indicated Patient Age Range
Not Found
Intended User / Care Setting
automated clinical chemistry analyzers
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3100 Amphetamine test system.
(a)
Identification. An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.(b)
Classification. Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
MAY - 2 2000
510(k) Summary
| Introduction | According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence. |
|---|---|
| 1) Submitter name, address, contact | Microgenics Corporation |
| 46360 Fremont Boulevard | |
| Fremont, CA 94538 | |
| (510) 979-5029 | |
| Fax: (510) 979-5229 | |
| Contact Person: Neal Bellet | |
| Date Prepared: April 20, 2000 | |
| 2) Device name | Proprietary name: CEDIA® DAU AmphAssure Assay |
| Common name: Homogeneous enzyme immunoassay for the determination of amphetamines in urine. | |
| Classification name: Amphetamine test system | |
| 3) Predicate device | We claim substantial equivalence to the TDx/TDxFLx |
| Amphetamine/Methamphetamine II Immunoassay (K883707) manufactured by Abbott Laboratories Inc. | |
| Continued on next page |
1
510(k) Summary, Continued
| 4) Device Description | The CEDIA® DAU AmphAssure assay uses recombinant DNA technology (US Patent No. 4708929) to produce a unique homogeneous enzyme immunoassay system. This assay is based on the bacterial enzyme B-galactosidase, which has been genetically engineered into two inactive fragments. These fragments spontaneously reassociate to form fully active enzyme that, in the assay format, cleaves a substrate, generating a color change that can be measured spectrophotometrically. The CEDIA DAU AmphAssure assay is a unique test for identification of amphetamines in urine and for the elimination of false positive results due to other cross-reactant substances. Most cross-reactive substances must be present in high concentrations compared to amphetamines in order to give a false-positive result in immunoassay based methods that detect amphetamines. AmphAssure employs the addition of a limited amount of a neutralizing antibody to amphetamine and methamphetamine to neutralize the signal in a true positive sample, without any effect on the signal from a sample containing a high concentration of cross-reactive substance. The neutralizing antibody does not bind the labeled conjugate in the assay, so that its primary effect is to reduce the signal resulting from amphetamines in the sample. Samples containing amphetamines can be distinguished from false- positive samples by the difference in signal before and after addition of the neutralizing antibody. Two analyzer channels are programmed with identical test parameters for the CEDIA AmphAssure assay; reagents without neutralization antibodies are assigned to the first channel, and the reagents with neutralization antibodies are assigned to the second channel. A calculated test (channel three) is programmed to give the difference in results between the first and second channel. Calibrators, controls and patient samples are tested on both channels.
The device consists of following: |
| ----------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
|---|
| AmphAssure Reagents | |
|---|---|
| 1 | EA Reconstitution Buffer |
- EA Reconstitution Buffer l Piperazine-N, N-bis [2-ethanesulfonic acid] buffer, buffer salts, stabilizer, and preservative la
- EA Reagent 0.16 g/l Enzyme Acceptor (microbial), 7 mg/l mouse monoclonal antibodies reactive to d-amphetamine and 7 mg/l mouse monoclonal antibodies reactive to d-methamphetamine, buffer salts, detergent, and preservative
- 2 ED Reconstitution Buffer Piperazine-N, N-bis [2-ethanesulfonic acid] buffer; buffer salts, and preservative
Continued on next page
2
510(K) Summary, Continued
| Device
Description
continued | 2a | ED Reagent
7.1 µg/l Enzyme Donor (microbial) conjugated to d-amphetamine
and 11.3 µg/l Enzyme Donor (microbial) conjugated to d-
methamphetamine, 1.7g/l chlorophenol red-b-D-galactopyranoside,
stabilizer, and preservative |
|------------------------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | 3 | EA Reconstitution Buffer
350 mg/l mouse monoclonal antibodies reactive to d-amphetamine
and d-methamphetamine, Piperazine-N, N-bis [2-ethanesulfonic acid]
buffer, buffer salts, stabilizer, and preservative |
| | 3a | EA Reagent
0.16 g/l Enzyme Acceptor (microbial), 7 mg/l mouse monoclonal
antibodies reactive to d-amphetamine and 7 mg/l mouse
monoclonal antibodies reactive to d-methamphetamine, buffer salts,
detergent, and preservative |
| | 4 | ED Reconstitution Buffer
Piperazine-N, N-bis [2-ethanesulfonic acid] buffer; buffer salts, and
preservative |
| | 4a | ED Reagent
7.1 µg/l Enzyme Donor (microbial) conjugated to d-amphetamine
and 11.3 µg/l Enzyme Donor (microbial) conjugated to
d-methamphetamine,
1.7 g/l chlorophenol red-b-D-galactopyranoside, stabilizer, and
preservative |
| | | AmphAssure Calibrator, Standard, and Control Set |
| | • | Upper Limit Standard
15,000 ng/ml d-methamphetamine in normal urine with preservative |
| | • | Cut-off Calibrator
375 ng/ml d-methamphetamine and 225K ng/ml pseudoephedrine in
normal urine with preservative |
| | | False Positive Control
500K ng/ml pseudoephedrine in normal urine with preservative |
| | | AmphAssure Calibrator, Standard and Control Kit is designed for use with
the AmphAssure assay only and will be packaged separately. |
3
- Intended use The CEDIA® DAU AmphAssure Assay is a homogeneous enzyme immunoassay for the in vitro qualitative determination of amphetamines in human urine on automated clinical chemistry analyzers. This device is used as an accessory to immunoassay screening tests to reduce the number of false positive results needing confirmation testing. Measurements are used as an aid in the diagnosis and treatment of amphetamine use or overdose.
The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. GCMS is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug of abuse test result particularly when preliminary positive test results are used.
6) Comparison to predicate device
The Microgenics Corporation CEDIA® DAU AmphAssure Assay is substantially equivalent to other products in commercial distribution intended for similar use. Most notably it is substantially equivalent to TDx/TDx FLx Amphetamine /Methamphetamine II (K883707) manufactured by Abbott Laboratory Inc.
The following table compares the CEDIA® DAU AmphAssure Assay with the predicate device, TDx/TDx FLx Amphetamine /Methamphetamine II.
| Similarities | Differences |
|---|---|
| Both assays utilize a monoclonal antibody. | The two assays have different monitoring systems: |
| AmphAssure (β-galactosidase hydrolysis of CPRG) | |
| TDX (Fluorescein tracer) | |
| Both assays yield negative results to ephedrine, pseudoephedrine, and phenylpropanolamine at concentrations of 1 mg/mL. | TDx uses periodate |
| Both assays are used to detect the presence of amphetamines in human urine | AmphAssure assay is a two-channel system that generate a difference in rate when amphetamines are present. |
| Both assays are run on automated clinical analyzers | TDx is semi-quantitative, whereas AmphAssure Assay is qualitative. |
4
Image /page/4/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services USA. The logo consists of a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the circumference. Inside the circle is a stylized symbol that resembles three overlapping profiles of human heads, with flowing lines suggesting movement or connection.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY - 2 2000
Mr. Andrew Morozovsky VP of Regulatory and Compliance Systems Microgenics Corporation 46360 Fremont Boulevard Fremont, California 94538
Re: K994380 Trade Name: CEDIA DAU AMPHASSURE Assay Regulatory Class: II Product Code: DKZ, DKB Dated: March 28, 2000 Received: March 29, 2000
Dear Mr. Morozovsky:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
510(k) Number (if known): N/A
(R) Device Name: CEDIA DAU AmphAssure Assay
Indications For Use:
The CEDIA® DAU AmphAssure Assay is a homogeneous enzyme immunoassay for the in vitro qualitative determination of amphetamines in human urine on automated clinical chemistry analyzers. This device is used as an accessory to immunoassay screening tests to reduce the number of false positive results needing confirmation testing. Measurements are used as an aid in the diagnosis and treatment of amphetamine use or overdose.
The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. GCMS is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug of abuse test result particularly when preliminary positive test results are used.
(Division Sign-Off) Division of Clinical Labora 129945 510(k) Number_
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)